Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis [Phase 3]

View source ↗

Summary

A Phase 3 trial compared daratumumab added to CyBorD versus CyBorD alone in newly diagnosed systemic AL amyloidosis, with results posted in March 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Amyloidosis | Phase 3 | Status: COMPLETED | Results posted: 2021-03-04